178 related articles for article (PubMed ID: 8339504)
1. Vitamin D status in Paget's bone disease. Effects of calcitonin therapy.
Nunziata V; Giannattasio R; di Giovanni G; Lettera AM; Nunziata CA
Clin Orthop Relat Res; 1993 Aug; (293):366-71. PubMed ID: 8339504
[TBL] [Abstract][Full Text] [Related]
2. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK
J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
[TBL] [Abstract][Full Text] [Related]
3. Abnormal vitamin D metabolism in Paget's disease of bone.
Guillard-Cumming DF; Beard DJ; Douglas DL; Johnson SK; Lawson-Matthew PJ; Russell RG; Kanis JA
Clin Endocrinol (Oxf); 1985 Apr; 22(4):559-66. PubMed ID: 3872746
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D in Paget's disease of bone.
Foldes J; Shamir S; Kidroni G; Menczel J
Clin Orthop Relat Res; 1989 Jun; (243):275-9. PubMed ID: 2498022
[TBL] [Abstract][Full Text] [Related]
5. Correlation between serum osteocalcin and 24,25-dihydroxyvitamin D levels in Paget's disease of bone.
Castro-Errecaborde N; de la Piedra C; Rapado A; Alvarez-Arroyo MV; Torres R; Traba ML
J Clin Endocrinol Metab; 1991 Feb; 72(2):462-6. PubMed ID: 1991815
[TBL] [Abstract][Full Text] [Related]
6. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Mortensen BM; Gautvik KM; Gordeladze JO
Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone, calcitonin and vitamin D metabolites in beta-thalassaemia major.
Zamboni G; Marradi P; Tagliaro F; Dorizzi R; Tatò L
Eur J Pediatr; 1986 Apr; 145(1-2):133-6. PubMed ID: 3015625
[TBL] [Abstract][Full Text] [Related]
8. [Calcitonin nasal spray for Paget's disease of the bone].
Luboshitzky R; Bar-Shalom R
Harefuah; 1995 Mar; 128(6):358-62, 399. PubMed ID: 7750816
[TBL] [Abstract][Full Text] [Related]
9. [Decrease of the coefficient of intestinal calcium absorption with normal blood levels of 1,25-dihydroxyvitamin D and decreasing levels of 24,25-dihydroxyvitamin D in Paget's disease of bone].
Traba ML; Climent P; Rapado A; de la Piedra C; Díaz Curiel M
Rev Clin Esp; 1986 Nov; 179(8):401-3. PubMed ID: 3494277
[No Abstract] [Full Text] [Related]
10. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
11. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
Chapuy MC; Meunier P; Terrier M; David L; Vignon G
Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of Paget's disease of bone with salmon calcitonin.
Sturtridge WC; Harrison JE; Wilson DR
Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231
[TBL] [Abstract][Full Text] [Related]
13. [Variations in parathormone serum levels during treatment of Paget's disease with calcitonin of human or salmon origin (author's transl)].
Heynen G; Franchimont P; Gaspar S; Gysen P; Kanis JA
Ann Endocrinol (Paris); 1981; 42(3):265-75. PubMed ID: 7316460
[TBL] [Abstract][Full Text] [Related]
14. One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray.
Reginster JY; Jeugmans-Huynen AM; Albert A; Denis D; Franchimont P
J Bone Miner Res; 1988 Jun; 3(3):249-52. PubMed ID: 3213619
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Paget's disease with salmon calcitonin].
Manderlier T; Fuss M; Brauman J; Orloff S; Bergans A; Corvilain J
Rev Rhum Mal Osteoartic; 1977 Jan; 44(1):59-66. PubMed ID: 319520
[No Abstract] [Full Text] [Related]
16. Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).
Rashid M; Khairi A; Johnston C
Clin Orthop Relat Res; 1977; (127):94-105. PubMed ID: 410576
[No Abstract] [Full Text] [Related]
17. Paget's disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment.
Avramides A; Flores A; DeRose J; Wallach S
J Clin Endocrinol Metab; 1976 Mar; 42(3):459-63. PubMed ID: 1254686
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin in the treatment of Paget's disease of bone.
Johnston CC
Ann Intern Med; 1972 Apr; 76(4):665-6. PubMed ID: 4268241
[No Abstract] [Full Text] [Related]
19. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
Drake S; Massie JD; Postlethwaite AE; Palmieri GM
Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
[TBL] [Abstract][Full Text] [Related]
20. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease.
Menaa C; Barsony J; Reddy SV; Cornish J; Cundy T; Roodman GD
J Bone Miner Res; 2000 Feb; 15(2):228-36. PubMed ID: 10703924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
